PLT 011
Alternative Names: Anti-PDL1/IL10 fusion protein - Pilatus Biosciences; PLT-011Latest Information Update: 06 Nov 2025
At a glance
- Originator Pilatus Biosciences
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 10 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Nov 2025 PLT 011 is available for licensing as of 06 Nov 2025. https://www.pilatusbio.com/business-development
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 01 Apr 2022 Preclinical trials in Cancer in Switzerland (unspecified route), before April 2022